Back HIV/AIDS

HIV / AIDS

HIV PrEP Forum Discusses Research, Personal Experiences, and Access

Nearly 100 people gathered on January 11 in San Francisco's Castro neighborhood to learn about the latest research on HIV pre-exposure prophylaxis -- better known as PrEP -- and how they can get help paying for it.

alt

Meta-Analysis Shows Injectable Hormonal Contraception Linked to HIV Infection Risk

Women who use the long-acting injectable contraceptive Depo-Provera had a modest but significant increase in the risk of contracting HIV infection, according to a meta-analysis of 12 studies published in the January 8Lancet Infectious Diseases. However, there was no increase in risk for women using birth control pills.

alt

1. HIV PrEP: Rising Use, Promising New Truvada Data, More Future Options

PrEP, or pre-exposure prophylaxis to prevent HIV infection, was the major HIV topic in the mainstream media in 2014. 

alt

Gilead and Janssen Announce Deal to Develop New TAF Single-Tablet Regimens

Gilead Sciences and Janssen R&D announced an agreement in late December to develop antiretroviral coformulations containing Gilead's novel tenofovir alafenamide (TAF) formulation and emtricitabine plus Janssen's HIV protease inhibitor darunavir (Prezista) or NNRTI rilpivirine (Edurant).

alt

4. HIV Cure Setbacks: Mississippi Baby and Bone Marrow Transplants

The quest for an HIV cure saw some setbacks in 2014, with further news about 2 stem cell transplant patients in Boston who experienced HIV rebound several months after interrupting antiretroviral therapy (ART). This was followed in July by an announcement that HIV was detected in a child in Mississippi who had maintained undetectable viral load for more than 2 years off treatment.

alt

Top 14 HIV and Hepatitis Stories of 2014

2014 was an exciting year in the fields of HIV and viral hepatitis, highlighted by growing awareness and promising new data for HIV pre-exposure prophylaxis (PrEP) and approval of highly effective new interferon-free combination pills for hepatitis C. But there were also some setbacks and challenges, including disappointments in HIV cure research and the high cost of the new hepatitis C drugs.

alt

5. HIV Treatment as Prevention: No Infections in PARTNER Study

Pre-exposure prophylaxis (PrEP) for HIV negative people was the biggest topic in HIV prevention in 2014, but use of antiretroviral therapy by HIV positive people to prevent onward transmission of the virus -- dubbed treatment as prevention or TasP -- also received further support.

alt